Xencor, Inc. (NASDAQ:XNCR) Stock Position Increased by Baillie Gifford & Co.

Baillie Gifford & Co. grew its position in Xencor, Inc. (NASDAQ:XNCR) by 3.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,530 shares of the biopharmaceutical company’s stock after purchasing an additional 744 shares during the period. Baillie Gifford & Co.’s holdings in Xencor were worth $445,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of XNCR. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Xencor by 2.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,798 shares of the biopharmaceutical company’s stock worth $654,000 after buying an additional 615 shares during the period. Louisiana State Employees Retirement System bought a new position in shares of Xencor in the fourth quarter worth $648,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Xencor by 13.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,215 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 1,640 shares in the last quarter. abrdn plc acquired a new position in shares of Xencor during the fourth quarter valued at $3,726,000. Finally, Signaturefd LLC raised its stake in shares of Xencor by 367.7% during the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,151 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have commented on XNCR. BMO Capital Markets restated an “outperform” rating and set a $32.00 price target on shares of Xencor in a research report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a research report on Tuesday, August 6th. JPMorgan Chase & Co. decreased their price target on Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Wedbush reissued an “outperform” rating and issued a $34.00 target price (down from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Finally, Raymond James reduced their price target on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.44.

Xencor Trading Up 6.0 %

Shares of NASDAQ:XNCR opened at $17.67 on Monday. The firm has a fifty day moving average of $18.67 and a two-hundred day moving average of $20.96. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 12-month low of $15.31 and a 12-month high of $26.84. The firm has a market capitalization of $1.09 billion, a P/E ratio of -8.07 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The firm had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business’s revenue for the quarter was down 62.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.37) EPS. On average, equities analysts expect that Xencor, Inc. will post -4.17 EPS for the current fiscal year.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 36,329 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the sale, the vice president now owns 192,319 shares in the company, valued at approximately $3,523,284.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.23% of the stock is currently owned by company insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.